Nevro (NVRO) Stock

Nevro (NVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

REDWOOD CITY, Calif. , Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on December 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,000 shares of Nevro's common stock to 20 new non-executive employees to induce them to accept employment with Nevro.

NVRO's continued technological innovations and business diversification plans raise optimism about the stock.

Select five stocks that have rising P/E ratios to explore a unique strategy. The stocks to consider are Stryve Foods, Nevro, Canoo, MSA Safety, and VTEX.

NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.

REDWOOD CITY, Calif. , Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro.

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif. , Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system.

NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago.